跳至主要内容
临床试验/NCT01703104
NCT01703104已完成1 期

The Effect of Jobelyn ( Extract of Sorghum Bicolor) on the Haematological Parameters of Patients With Sickle Cell Anaemia Disease.

Lagos State University1 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2012年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
150
试验地点
1
主要终点
Number of Participants with Adverse Events

研究概览

简要总结

The primary objective is to determine if there is a significant increase in the haematocrit value of patients on Jobelyn and standard therapy compared to those on standard therapy alone.

详细描述

Sickle cell anaemia is an inherited haemoglobinopathy caused by a point missense mutation (GAG to GTG) in the beta globin gene that resulted in the substitution of an acidic amino acid ( glutamic acid) with a neutral and hydrophobic amino acid (valine) in the codon 6 of the beta globin chain. This genetic defect has a prevalence of 20% to 40% in Sub Saharan Africa, 7.8% in African Americans and to a lesser extent in the Middle East, Mediterranean and India.

The higher frequency in the sub Saharan Africa is thought to be due to the selective advantage the gene confers on the traits (heterozygotes state) in malaria zone. Nigeria is the most populous country in this region with about 24% frequency of the mutant gene. The prevalence of sickle cell anaemia in Nigeria is about 20 per 1000 life births. This implies that Nigeria may have the highest burden of the disease in the world.

The severity of sickle cell disease varies. The disease is more severe in patients with haemoglobin SS or haemoglobin S beta thalassaemia than in those with haemoglobin S beta+ thalassaemia or haemoglobin SC disease. The Arab - Indian haplotype produces a less severe disease than the African haplotype. Similarly, the coinheritance of one or two, alpha globin chain deletions or high fetal haemoglobin level in hereditary persistence of fetal haemoglobin are associated with mild disease, The severity is therefore higher in the Sub Saharan African sub region. However, the severity of the disease varies widely for unexplained reasons among patients with haemoglobin SS in this region.

The beta S globin chain binds at the valine site with complementary hydrophobic effects on other beta globin chain. This triggers the formation of polymers of haemoglobin. The rate of polymerization is increased with increase in intracellular deoxy-haemoglobin. Factors that promote polymerisation are dehydration, acidosis, increase in the level of 2,3 diphosphoglycerate which may occur in infections. On the other hand, the association of haemoglobin 5 with other haemoglobin that have higher oxygen affinity-like haemoglobin F or haemoglobin A reduce the rate of polymerisation.

The haemoglobin polymer forms a firm gel that damages the cellular membrane. The damaged membrane causes movement of potassium and water out of the cell thus leading to dehydration and more polymer formation. This damage also causes the negatively charged phosphatidylserine to move to the membrane surface and the red cell becomes deformed in shape, more rigid and more adherent to the vascular endothelium. The result of these are easy fragmentation of the membrane and extra vascular haemolysis, complement mediated lysis of the cell and intravascular haemolysis, shortened red cell survival to 4 to 25 days, trapping of rigid irreversible sickle cells in the post capillary venules which is promoted by leukocytosis, platelet activation and inflammatory cytokines.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Single (Care Provider)

入排标准

年龄范围
14 Years 至 45 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female 14 to 45 years of age
  • Haemoglobin SS

排除标准

  • Patients with chronic inflammatory disease like tuberculosis
  • Patients with chronic viral hepatitis or positive for human immunodeficiency virus
  • Patients with autoimmune disorders.
  • . patients with other haemoglobinopathy
  • Pregnancy or anticipated pregnancy.
  • Patient on drug abuse or alcohol abuse.
  • Patients on treatment for organ failure

研究组 & 干预措施

Paludrine + Folic Acid

Active Comparator

This arm uses routine drugs, Paludrine + Folic Acid

干预措施: Paludrine + Folic Acid (Drug)

Paludrine + Folic Acid + Jobelyn

Active Comparator

This group uses Paludrine + Folic Acid + Jobelyn

干预措施: Paludrine + Folic Acid + Jobelyn (Dietary Supplement)

结局指标

主要结局

Number of Participants with Adverse Events

时间窗: 12 weeks

The number of participants who reported with Adverse events for the 12-week duration of the study

次要结局

  • number of blood transfusions during the 12-week trial period(12 weeks)

研究者

发起方
Lagos State University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Dr. A. O. Dosunmu

CONSULTANT IN THE DEPARTMENT OF HAEMATOLOGY & BLOOD TRANSFUSION, LASUTH

Lagos State University

研究点 (1)

Loading locations...

相似试验